Back to Search Start Over

hPCL3S promotes proliferation and migration of androgen-independent prostate cancer cells.

Authors :
Abdelfettah S
Boulay G
Dubuissez M
Spruyt N
Garcia SP
Rengarajan S
Loison I
Leroy X
Rivera MN
Leprince D
Source :
Oncotarget [Oncotarget] 2020 Mar 24; Vol. 11 (12), pp. 1051-1074. Date of Electronic Publication: 2020 Mar 24 (Print Publication: 2020).
Publication Year :
2020

Abstract

Polycomb repressive complex 2 (PRC2) allows the deposition of H3K27me3. PRC2 facultative subunits modulate its activity and recruitment such as hPCL3/PHF19, a human ortholog of Drosophila Polycomb-like protein (PCL). These proteins contain a TUDOR domain binding H3K36me3, two PHD domains and a "Winged-helix" domain involved in GC-rich DNA binding. The human PCL3 locus encodes the full-length hPCL3L protein and a shorter isoform, hPCL3S containing the TUDOR and PHD1 domains only. In this study, we demonstrated by RT-qPCR analyses of 25 prostate tumors that hPCL3S is frequently up-regulated. In addition, hPCL3S is overexpressed in the androgen-independent DU145 and PC3 cells, but not in the androgen-dependent LNCaP cells. hPCL3S knockdown decreased the proliferation and migration of DU145 and PC3 whereas its forced expression into LNCaP increased these properties. A mutant hPCL3S unable to bind H3K36me3 (TUDOR-W50A) increased proliferation and migration of LNCaP similarly to wt hPCL3S whereas inactivation of its PHD1 domain decreased proliferation. These effects partially relied on the up-regulation of genes known to be important for the proliferation and/or migration of prostate cancer cells such as S100A16, PlexinA2 , and Spondin1 . Collectively, our results suggest hPCL3S as a new potential therapeutic target in castration resistant prostate cancers.<br />Competing Interests: CONFLICTS OF INTEREST The authors declare no disclosure of potential conflicts of interest.

Details

Language :
English
ISSN :
1949-2553
Volume :
11
Issue :
12
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
32256978
Full Text :
https://doi.org/10.18632/oncotarget.27511